ProfoundBio discovers the joys of having a wealthy owner
The company has become the latest in a recent string of China-related innovative drug makers to be purchased by larger foreign buyers Key Takeaways: Cancer treatment maker ProfoundBio announced it…
GenScript losses shrink on strong growth for cancer cell therapy
The pharma company’s losses narrowed 58% last year, as its life sciences and cell therapy businesses experienced strong growth Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year…
Adlai Nortye dives in Nasdaq debut, as key product faces hurdles
Shares of the drug maker that licenses its products from other companies lost more than half their value in the two weeks after their listing Key Takeaways: Newly listed Adlai…
FAST NEWS: Beigene stock falls after Novartis terminates partnership
The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Tuesday that Novartis (NOVN.SWX) will relinquish its rights to co-develop, produce and commercialize BeiGene’s esophagus cancer drug tislelizumab. Looking up: Novartis will provide…
Sales success comes with side effects for drug maker BeiGene
The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs Key Takeaways: Global sales of BeiGene's anti-tumor drug zanubrutinib…
Laekna IPO hopes to hitch a ride on Novartis ties
The producer of drugs licensed from third parties is banking on ties to the Swiss drug maker, as one of its key products nears the regulatory finish line Key Takeaways:…
FAST NEWS: Antengene Appoints New Chief Medical Officer
The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) said on Wednesday Kevin Patrick Lynch has resigned as an executive director and chief medical officer (CMO) to retire, but will remain…
Recent Articles
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
Everest reaches new heights on growing drug sales
1952.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
